About Plexium:
Plexium is the premier, next-generation Targeted Protein Degradation (TPD) company focused on the discovery of TPD drugs which overcome limitations of conventional approaches to broaden the therapeutic potential of TPD. Plexium is pursuing monovalent degraders, including a new class of selective TPD drugs called “Direct Degraders.” Direct Degraders are small molecules that are designed to bind to a pathogenic protein in a manner that results in selective degradation of the protein by the cell’s natural protein quality control machinery. In addition to direct degraders, Plexium is pursuing molecular glue degraders. This approach also leverages the cell’s natural quality control machinery, however in this case, small molecules bind to an E3 ligase, redirecting the ligase to selectively target pathogenic proteins for degradation. Plexium is pursuing drug targets that have previously been undruggable or inadequately drugged across multiple disease areas.
Plexium is powered by its proprietary TPD drug discovery platform which integrates degrader chemistry design principles and screening libraries with cell-based, target-specific degradation assays, including an ultra-high-throughput screening platform, to enable the identification of drug-like, cell-permeable degrader molecules. This integrated TPD drug discovery approach has led to the discovery of novel, selective direct degraders and molecular glue drug candidates, and two unprecedented E3 ligases.